Cargando…

Clinically-Relevant Weight Loss is Achieved Independently of Early Weight Loss Response to Once-Weekly Subcutaneous Semaglutide 2.4 MG (STEP 4)

Background: Semaglutide, a glucagon-like peptide-1 analogue, is being investigated in people with overweight or obesity. A post-hoc analysis of the STEP 4 trial was conducted to identify whether early weight loss is predictive of later weight loss with maintenance once-weekly subcutaneous (s.c.) sem...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mosenzon, Ofri, Garvey, W Timothy, Hesse, Dan, Koroleva, Anna, Kushner, Robert F, Lim, Soo, Lingvay, Ildiko, Wallenstein, Signe O R, Wadden, Thomas A, Le Roux, Carel W
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Adipose Tissue, Appetite, and Obesity
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8265765/ http://dx.doi.org/10.1210/jendso/bvab048.013

Ejemplares similares

Once-weekly Subcutaneous Semaglutide 2.4 mg Reduces Body Weight in Adults with Overweight or Obesity Regardless of Baseline Characteristics (STEP 1)
por: Kushner, Robert F, et al.
Publicado: (2021)

Weight Loss Maintenance With Once-Weekly Semaglutide 2.4 MG in Adults With Overweight or Obesity Reaching Maintenance Dose (STEP 4)
por: Rubino, Domenica M, et al.
Publicado: (2021)

Efficacy and Safety of Once-Weekly Subcutaneous Semaglutide 2.4 MG in Adults With Overweight or Obesity (STEP 1)
por: Wilding, John P H, et al.
Publicado: (2021)

Efficacy and Safety of Semaglutide 2.4 MG Once-Weekly in Adults With Overweight or Obesity and Type 2 Diabetes (STEP 2)
por: Davies, Melanie, et al.
Publicado: (2021)

Preclinical Weight Loss Efficacy of AM833 in Combination With Semaglutide in Rodent Models of Obesity
por: John, Linu M, et al.
Publicado: (2021)

Safety and Tolerability of Concomitant Administration of Multiple-Dose AM833 With Semaglutide 2.4 MG for Weight Management
por: Enebo, Lone B, et al.
Publicado: (2021)

Abstract 9: Once-weekly subcutaneous semaglutide 2.4 mg reduces body weight in adults with overweight or obesity regardless of baseline characteristics (STEP 1)
por: Suresh, Swaroop H, et al.
Publicado: (2022)

SAT-097 Weight Loss With Liraglutide 3.0 Mg Versus Placebo For Individuals Who Adhere To The Trial Drug: A Secondary Analysis From SCALE IBT
por: Shaw Tronieri, Jena, et al.
Publicado: (2019)

Once-Weekly Exenatide Enhances Weight Loss Maintenance in Adolescents with Severe Obesity: A Randomized, Placebo-Controlled Trial
por: Fox, Claudia K, et al.
Publicado: (2021)

SAT-105 Weight Loss As Determined By Adherence To Reduced Caloric Diet, Increased Physical Activity, Liraglutide 3.0 Mg and Placebo: A Sub-analysis Of The SCALE IBT Trial
por: Shaw Tronieri, Jena, et al.
Publicado: (2019)

MON-120 Effect of Weight Loss on Physical Function Measured by the 6-Minute Walking Distance Test in Individuals with Obesity: Results from the SCALE IBT Trial of Liraglutide 3.0 Mg
por: Rubino, Domenica, et al.
Publicado: (2019)

SAT-102 Self-efficacy As A Predictor Of Weight Loss In Veterans With Obesity Participating In Medical Weight Management.
por: Parziale, Andrew, et al.
Publicado: (2019)

MON-095 Phentermine Induces Weight Loss in Prader-Willi Syndrome
por: Mottalib, Adham, et al.
Publicado: (2019)

SAT-095 The Impact of CPAP on Intensive Calorie Restriction Weight Loss
por: Mao, Yuanjie, et al.
Publicado: (2019)

Weight Loss Mobile Apps: Do They Address COVID-19 and Diabetes
por: Wu, Gloria, et al.
Publicado: (2021)

MON-LB100 Novel Paradoxical Markers of Weight Loss: Is the Worse Actually the Better? a Retrospectiveanalysisof 1,567 Patientswith Obesity With Successful Clinical Weight-Loss Approaches
por: Cadegiani, Flavio, et al.
Publicado: (2020)

OR10-02 Effect Of Phosphodiesterase 4 Inhibitors On Weight Loss And Energy Homeostasis In Mice With Obesity Induced By A High-fat-diet
por: de Andrade, Maria Amelia A M, et al.
Publicado: (2023)

Is Insulin Resistance at Baseline a Predictor of Weight Loss After Bariatric Surgery?
por: Borges-Canha, Marta, et al.
Publicado: (2021)

RF24 | PSUN95 Defining Predictors of Weight Loss Response to Lorcaserin
por: Gugger, Aristea Sideri, et al.
Publicado: (2022)

FRI074 Rise In Fasting Ghrelin Level In Response To Weight Loss Predicts Future Weight Regain In The POUNDS LOST Trial
por: Tong, Jenny, et al.
Publicado: (2023)

MON-590 Presence of Diabetes Diminishes the Ultimate Weight Loss After Bariatric Surgery
por: Luo, Yingying, et al.
Publicado: (2020)

Weight Loss, Improved Body Composition and Fat Distribution by Tesomet in Acquired Hypothalamic Obesity
por: Huynh, Kim D, et al.
Publicado: (2021)

Impact of Semaglutide on Body Composition in Adults With Overweight or Obesity: Exploratory Analysis of the STEP 1 Study
por: Wilding, John P H, et al.
Publicado: (2021)

MON-109 Identifying Limiting Factors to Weight Loss and Prevention of Comorbidities in a Patient Population with Obesity
por: Johns, Allison, et al.
Publicado: (2019)

MON-LB102 Metformin-Induced Weight Loss in Patients With or Without Type 2 Diabetes/Prediabetes
por: Chukir, Tariq, et al.
Publicado: (2020)

Engagement in a Multi-Feature Digital Health Lifestyle Change Program as a Predictor of Weight Loss
por: Dzubur, Eldin, et al.
Publicado: (2021)

ODP008 Nonalcoholic Fatty Liver Disease (NAFLD) Impacts Weight Loss after Bariatric Surgery
por: Abu-Rumaileh, Mohammed, et al.
Publicado: (2022)

ODP591 Obesity and Weight Loss Apps in COVID-19 Era: Do They Help Both the Doctor and the Patient?
por: Lawrence, Rebecca, et al.
Publicado: (2022)

OR10-3 Long-term Weight Loss Maintenance with Obesity Pharmacotherapy: a 5-Year Retrospective Study
por: Andre, Clarissa, et al.
Publicado: (2022)

SUN-602 Weight Loss After Glucagon-Like Peptide-1 Receptor Agonist Treatment in Childhood Obesity with Diabetes and Cirrhosis Associated with a Homozygous MC4R Mutation
por: Klee, Philippe, et al.
Publicado: (2020)

FRI075 Single Center Retrospective Matched Cohort Study Of glp1ra-induced Weight Loss In Patients With Post-bariatric Weight Regain Vs Non-surgical Controls
por: Carmen Rivadeneira, Ana Del, et al.
Publicado: (2023)

MON-094 Aromatase Inhibitors and Weight Loss in Severely Obese Male Veterans with Hypogonadism: A Randomized Clinical Trial
por: Colleluori, Georgia, et al.
Publicado: (2019)

No Differences in Metabolic Parameters Between Roux-en-Y Gastric Bypass and Sleeve Gastrectomy, Regardless of Achieved Weight Loss
por: Holanda, Narriane Chaves Pereira, et al.
Publicado: (2021)

SAT-119 Effect of Binge Eating Diagnosed Prior to Bariatric Surgery on Weight Loss up to 2 Years after Surgery
por: Friedman, Rogerio, et al.
Publicado: (2019)

SAT-108 Effects of Bariatric and Non-Bariatric Weight Loss on Migraine Headache in Obesity. A Systematic Review and Meta-Analysis
por: Di Vincenzo, Angelo, et al.
Publicado: (2019)

Low Health Literate State Does Not Negatively Affect Final Weight Loss After a Laparoscopic Gastric Bypass Procedure
por: Twickler, Theodorus Bartholomeus, et al.
Publicado: (2021)

MON-LB107 Treat: A Randomized Controlled Trial Examining the Effects of Time Restricted Eating on Weight Loss and Metabolic Markers
por: Lowe, Dylan A, et al.
Publicado: (2020)

FRI078 Real-World Weight Loss Outcomes And Safety Of Tirzepatide, A Novel Dual GIP And GLP-1 Receptor Agonist
por: Fansa, Sima, et al.
Publicado: (2023)

MON-LB019 Setmelanotide (RM-493) Reduces Food Intake and Rapidly Induces Weight Loss in a Mouse Model of Alström Syndrome
por: Stephenson, Erin, et al.
Publicado: (2019)

SUN-113 Adipocyte Morphology And Cytokine Gene Expression In Adipose Tissue From Patients Before And After Weight Loss From Bariatric Surgery
por: Casimiro, Isabel, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_gle4e6iefh6vv5k46jonjot40m